Skip to NavigationSkip to content

News

From narrow trial misses to dire Brexit health forecasts, check out the top ten most popular articles on Pharmafile.com this week!
Roche has confirmed that its immunotherapy Tecentriq (atezolizumab) has been approved in Europe in combination with chemotherapy (carboplatin and...
Novartis has made the surprise announcement that its VEGF inhibitor Lucentis (ranibizumab) has been awarded marketing authorisation from the...
Novartis is celebrating the acceptance of its experimental cancer drug capmatinib by the FDA onto an accelerated review pathway, securing the...
The public have always been reticent with their trust in the pharmaceutical industry, but that trust has hit an all-time low as a new Gallup poll...
Boehringer Ingelheim is set to join forces with Lupin after the pair sealed a partnership agreement to develop, license, and commercialise the...
Janssen has announced that its therapy Stelara (ustekinumab) hass secured a label expansion from the European Commission, approving the drug in the...
Bristol-Myers Squibb has revealed that its blockbuster immunotherapy Opdivo (nivolumab) fell short of its primary Phase 3 endpoint in the treatment...
The number of cancer drug approvals in the US has surged over the last decade to account for over one in four of all therapy authorisations from...
Though MPs are moving forward with their plan to block UK Prime Minister Boris Johnson’s supposed no-deal Brexit from the EU and the economic and...
Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches